Fulcrum Therapeutics Inc FULC shares are trading higher after the FDA lifted the clinical hold on the Investigational New Drug (IND) application for FTX-6058 for the potential treatment of sickle-cell disease (SCD). "Based on the initial data from the Phase 1b trial, which showed increasing levels…
#fda #ftx6058 #scd #hbf #alexsapir #fulcrum
Continue reading...
